Genaissance starts pharmacogenetics study

GNSC began its 600-patient U.S. Statin Response Examined by Genetic HAP Markers (STRENGTH) study. Patients with hypercholesterolemia will receive either Lipitor atorvastatin from Pfizer (PFE); Zocor s...